The Study Of Percutaneous Trans-splenic Varices Embolization & Metallic Stenting In Treatment Of Tumor Thrombus In Portal Vein Of Primary Liver Cancer

Part One: The Study of Biodegradable Polymeric PLGA Coated Stent Carrying with Epirubicin and of Inhibiting Carcinoma in VivoObjective: To investigate the biodegraded polymeric PLGA (polylactic acid /polyglycolic acid copolymer) coated stent, carrying with epirubicin, and its anti-carcinoma ability was validated by hepatic cancerous cell cultured in vivo. Materials and Methods: The biodegraded PLGA, carrying with epirubicin, was coated on metallic stents equably. The stents were scanned by scanning electron microscope, and the compound dosage was measured. The stents were cut into 7mm╳7mm pieces and put into culture medium which incubated human hepatic cancerous cells (SMMC7721). The same cells with pieces of naked stents and none stents were cultured as contrast. All cells were cultured for 72 hour, and observed under optical microscope and recorded. Results: (1) The stents coated with membrane were smooth, and event without obvious crack and hole under scanning electron microscopic view. (2) The mean PLGA dosage was 194.86±8.32μg, epirubicin was 194.75±3.62μg per stent. (3) After 72 hour, almost all cells, which were cultured with membraned stent pieces, were dead. Only few remaining dead round cells, floating in upper culture medium, and some apoptosis cells and pieces of cell were visible. It can't be counted since none alive cell was visible. The cells in contrast groups, with naked stent pieces and with none stent, grew well. Conclusions: (1) The membraned stents were smooth, which were fitted to standard using for vessels. (2) The membrane was degraded in 2~3 months. The dosage of PLGA and epirubicin were 194.86±8.32μg and 194.75±3.62μg per stent respectively. (3) It manifested that the membraned stent can inhibit hepatic cancerous cells growth in vivo.